FindTrial
Sign In

A Randomized, Double-blind, Placebo-controlled Study in Hemodialysis Patients with Secondary Hyperparathyroidism

A Randomized, Double-blind, Placebo-controlled Study in Hemodialysis Patients with Secondary Hyperparathyroidism

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080220083
Enrollment
Unknown
Registered
2005-09-12
Start date
2005-09-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary hyperparathyroidism in hemodialysis patients

Interventions

investigational material(s) Generic name etc : KRN1493 INN of investigational material : Therapeutic category code : 399 Agents affecting metabolism, n.e.c. Dosage and Administration for Investigatio

Sponsors

Kyowa Hakko Kirin Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Hemodialysis patients with secondary hyperparathyroidism

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Efficacy (efficacy ratio using serum intact PTH, others) Safety—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026